How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries
Sabine Vogler (sabine.vogler@goeg.at),
Valérie Paris,
Alessandra Ferrario,
Veronika J. Wirtz,
Kees Joncheere,
Peter Schneider,
Hanne Bak Pedersen,
Guillaume Dedet and
Zaheer-Ud-Din Babar
Additional contact information
Sabine Vogler: Pharmacoeconomics Department, Gesundheit Österreich GmbH (Austrian Public Health Institute)
Valérie Paris: Organisation for Economic Co-operation and Development (OECD)
Alessandra Ferrario: London School of Economics and Political Science
Veronika J. Wirtz: Boston University School of Public Health
Kees Joncheere: World Health Organization (WHO)
Peter Schneider: Pharmacoeconomics Department, Gesundheit Österreich GmbH (Austrian Public Health Institute)
Hanne Bak Pedersen: World Health Organization (WHO) Regional Office for Europe
Guillaume Dedet: World Health Organization (WHO) Regional Office for Europe
Zaheer-Ud-Din Babar: University of Auckland
Applied Health Economics and Health Policy, 2017, vol. 15, issue 3, No 4, 307-321
Abstract:
Abstract This article discusses pharmaceutical pricing and reimbursement policies in European countries with regard to their ability to ensure affordable access to medicines. A frequently applied pricing policy is external price referencing. While it provides some benchmark for policy-makers and has been shown to be able to generate savings, it may also contribute to delay in product launch in countries where medicine prices are low. Value-based pricing has been proposed as a policy that promotes access while rewarding useful innovation; however, implementing it has proven quite challenging. For high-priced medicines, managed-entry agreements are increasingly used. These agreements allow policy-makers to manage uncertainty and obtain lower prices. They can also facilitate earlier market access in case of limited evidence about added therapeutic value of the medicine. However, these agreements raise transparency concerns due to the confidentiality clause. Tendering as used in the hospital and offpatent outpatient sectors has been proven to reduce medicine prices but it requires a robust framework and appropriate design with clear strategic goals in order to prevent shortages. These pricing and reimbursement policies are supplemented by the widespread use of Health Technology Assessment to inform decision-making, and by strategies to improve the uptake of generics, and also biosimilars. While European countries have been implementing a set of policy options, there is a lack of thorough impact assessments of several pricing and reimbursement policies on affordable access. Increased cooperation between authorities, experience sharing and improving transparency on price information, including the disclosure of confidential discounts, are opportunities to address current challenges.
Keywords: Health Technology Assessment; Reimbursement Policy; Agalsidase Beta; Parallel Trade; Medicine Price (search for similar items in EconPapers)
Date: 2017
References: Add references at CitEc
Citations: View citations in EconPapers (17)
Downloads: (external link)
http://link.springer.com/10.1007/s40258-016-0300-z Abstract (text/html)
Access to the full text of the articles in this series is restricted.
Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
HTML/Text
Persistent link: https://EconPapers.repec.org/RePEc:spr:aphecp:v:15:y:2017:i:3:d:10.1007_s40258-016-0300-z
Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40258
DOI: 10.1007/s40258-016-0300-z
Access Statistics for this article
Applied Health Economics and Health Policy is currently edited by Timothy Wrightson
More articles in Applied Health Economics and Health Policy from Springer
Bibliographic data for series maintained by Sonal Shukla (sonal.shukla@springer.com) and Springer Nature Abstracting and Indexing (indexing@springernature.com).